Professional
Added to YB: 2025-09-29
Pitch date: 2025-07-14
ALNY [bullish]
Alnylam Pharmaceuticals, Inc.
+7.09%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Market Cap
$41.7B
Pitch Price
$316.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
66.11
P/E
134.94
EV/Sales
11.24
Sector
Biotechnology
Category
growth
Show full summary:
Parnassus Mid Cap Growth Fund New Position: Alnylam Pharmaceuticals, Inc.
ALNY (new position): Pioneer in RNA interference therapeutics w/ innovative platform & expanding product portfolio in cardiomyopathy. Healthy cash balance provides high-quality biotech exposure. Strong long-term growth potential from novel medicine class.
Read full article (1 min)